KR20140014062A - 항-에프린 ｂ2 항체 및 이의 용도 - Google Patents

항-에프린 ｂ2 항체 및 이의 용도 Download PDF

Info

Publication number
KR20140014062A
KR20140014062A KR1020137007045A KR20137007045A KR20140014062A KR 20140014062 A KR20140014062 A KR 20140014062A KR 1020137007045 A KR1020137007045 A KR 1020137007045A KR 20137007045 A KR20137007045 A KR 20137007045A KR 20140014062 A KR20140014062 A KR 20140014062A
Authority
KR
South Korea
Prior art keywords
polypeptide
antibody
cell
ephrin
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137007045A
Other languages
English (en)
Korean (ko)
Inventor
토레쿠아드라다 조르지 루이스 마르티네즈
인판테스 마리아 안젤레스 아벤고자르
Original Assignee
푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 (씨엔아이오)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 (씨엔아이오) filed Critical 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 (씨엔아이오)
Publication of KR20140014062A publication Critical patent/KR20140014062A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137007045A 2010-09-21 2011-09-20 항-에프린 ｂ2 항체 및 이의 용도 Withdrawn KR20140014062A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201031402 2010-09-21
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (1)

Publication Number Publication Date
KR20140014062A true KR20140014062A (ko) 2014-02-05

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137007045A Withdrawn KR20140014062A (ko) 2010-09-21 2011-09-20 항-에프린 ｂ2 항체 및 이의 용도

Country Status (12)

Country Link
US (1) US9062109B2 (enExample)
EP (1) EP2620449A4 (enExample)
JP (1) JP2013542720A (enExample)
KR (1) KR20140014062A (enExample)
CN (1) CN103237812A (enExample)
AU (1) AU2011306816A1 (enExample)
BR (1) BR112013005977A2 (enExample)
CA (1) CA2812727A1 (enExample)
ES (1) ES2378976B1 (enExample)
MX (1) MX2013003168A (enExample)
RU (1) RU2013118454A (enExample)
WO (1) WO2012038573A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
US20220213214A1 (en) * 2019-05-14 2022-07-07 Sanford Health Anti-human ephrin B1 antibodies and uses thereof
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
TW202547871A (zh) * 2024-03-27 2025-12-16 美商麥第爾醫療公司 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法
CN121159668A (zh) * 2025-09-12 2025-12-19 北京威斯克生物医药有限公司 Ephrin-B2重组蛋白及其疫苗、制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
EP1954720A1 (en) * 2005-10-31 2008-08-13 The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health Antibodies and immunotoxins that target human glycoprotein nmb
RU2451031C2 (ru) * 2006-01-20 2012-05-20 Дженентек, Инк. Антитела к эфрину в2 и способы их применения
PL1972637T3 (pl) * 2007-03-19 2012-01-31 Univ Stuttgart Antagoniści selektywni wobec huTNFR1
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Also Published As

Publication number Publication date
CN103237812A (zh) 2013-08-07
WO2012038573A1 (es) 2012-03-29
CA2812727A1 (en) 2012-03-29
MX2013003168A (es) 2013-08-21
US9062109B2 (en) 2015-06-23
US20130287795A1 (en) 2013-10-31
EP2620449A1 (en) 2013-07-31
ES2378976B1 (es) 2013-05-06
RU2013118454A (ru) 2014-10-27
EP2620449A4 (en) 2014-03-26
JP2013542720A (ja) 2013-11-28
BR112013005977A2 (pt) 2019-09-24
AU2011306816A1 (en) 2013-04-04
ES2378976A1 (es) 2012-04-19

Similar Documents

Publication Publication Date Title
US20240343824A1 (en) Binding molecules that inhibit cancer growth
JP2021507925A (ja) Ｇｐｃｒヘテロマー阻害剤及びその用途
AU2022287100A1 (en) Bispecific binding molecule binding vegf and ang2 and use thereof
US9062109B2 (en) Anti-ephrin-B2 antibody and compositions comprising it
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
AU2017273169A1 (en) Method for screening antibody using patient-derived tumor spheroids
WO2019054819A1 (ko) 라이실 tRNA 합성효소 N-말단에 특이적으로 결합하는 항체를 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
US20210155709A1 (en) Antibodies anti tumor associated antigens and method for obtaining them
CN110734494B (zh) 抗tspan8单克隆抗体及其用途
CN119390838B (zh) 一种靶向ccr7的纳米抗体及其制备与应用
HK40062651A (en) Binding molecules that inhibit cancer growth
EA051189B1 (ru) Связывающие молекулы, которые ингибируют рост рака
HK1253914B (en) Binding molecules that inhibit cancer growth
IL258866B1 (en) Binding molecules that inhibit cancer growth

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid